---
document_datetime: 2025-07-04 18:30:06
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hyftor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: hyftor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5498914
conversion_datetime: 2025-12-26 17:34:28.54984
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## HYFTOR

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | This was an application for a group of | 04/07/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000282602                     | variations. B.II.b.1 Replacement or addition of a manufacturingsiteforpartorallofthe manufacturing process of the finished product - B.1I1.b.1.a Secondary packaging site -Accepted B.II.b.2.cReplacement or addition of a manufacturer responsible for importation and/orbatch release-B.I1.b.2.c.1 Not includingbatchcontrol/testing-Accepted   |            |     | PL   |                                                                                                                                                                                                                                                                                                         |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000252921 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.zOther variation-Accepted Toupdate theenvironmentalrisk assessment by submit a study of transformationinwater/sedimentsystems (OECD308)asnextstepofthePBT assessmentforSirolimus.                                                                                                                     | 07/04/2025 | N/A |      |                                                                                                                                                                                                                                                                                                         |
| PSUR/EMA/PSUR/0000248441              |                                                                                                                                                                                                                                                                                                                                                   |            |     |      | Basedon thePRACreviewofdataonsafety and efficacy,thePRACconsidersthattherisk-benefit balance of medicinal products containing sirolimus (indicatedfortreatmentofangiofibromaassociated withtuberoussclerosiscomplex)remains unchangedand thereforerecommendsthe maintenanceofthemarketingauthorisation. |